膀胱癌（BC）是常见的泌尿系统肿瘤，具有较高的复发率。铜死亡和长非编码RNA（lncRNA）在许多恶性肿瘤的肿瘤发生中发挥重要作用。然而，铜死亡相关lncRNA（CRLs）在BC中的预后价值尚不清楚。本研究所使用的公共数据来自癌症基因组图谱数据库。对铜死亡相关基因的表达谱、突变、共表达和富集分析进行了广泛探索。使用Pearson相关分析鉴定了466个CRLs。然后，通过单变量Cox回归筛选出16个预后相关的CRLs。无监督聚类将患者分为两个簇，具有不同的生存结果。使用最小绝对收缩和选择算子（LASSO）Cox回归分析构建了由7个CRLs组成的标志。生存曲线和受试者工作特征显示预后标志具有良好的预测价值，并在测试和整个数据集中得到验证。通过分层分析进一步确认了我们标志的可靠性和稳定性。此外，基于标志的风险评分被确认为独立的预后因子。基因组富集分析显示高风险组中的分子改变与癌症密切相关。然后，我们利用独立的预后指标开发了临床计量图。值得注意的是，高风险组中的免疫细胞浸润和免疫检查点的表达较高，表明他们可能更受免疫治疗的益处。总结来说，预后标记可以有效预测预后，并为BC患者的临床治疗提供新的见解。

Bladder cancer (BC) is a common urologic tumor with a high recurrence rate. Cuproptosis and long noncoding RNAs (lncRNAs) have demonstrated essential roles in the tumorigenesis of many malignancies. Nevertheless, the prognostic value of cuproptosis-related lncRNA (CRLs) in BC is still unclear. The public data used for this study were acquired from the Cancer Genome Atlas database. A comprehensive exploration of the expression profile, mutation, co-expression, and enrichment analyses of cuproptosis-related genes was performed. A total of 466 CRLs were identified using Pearson's correlation analysis. 16 prognostic CRLs were then retained by univariate Cox regression. Unsupervised clustering divided the patients into two clusters with diverse survival outcomes. The signature consists of 7 CRLs was constructed using the least absolute shrinkage and selection operator (LASSO) Cox regression analyses. Survival curves and receiver operating characteristics showed the prognostic signature possessed good predictive value, which was validated in the testing and entire sets. The reliability and stability of our signature were further confirmed by stratified analysis. Additionally, the signature-based risk score was confirmed as an independent prognostic factor. Gene set enrichment analysis showed molecular alteration in the high-risk group was closely associated with cancer. We then developed the clinical nomogram using independent prognostic indicators. Notably, the infiltration of immune cells and expression of immune checkpoints were higher in the high-risk group, suggesting that they may benefit more from immunotherapy. In summary, the prognostic signature might effectively predict the prognosis and provide new insight into the clinical treatment of BC patients.